Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.56 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isothiocyanate SCHEMBL29287688 | 0.91 | NPC1 (0.59) | NPC1RAB9AAKR1C3AKR1C2PTPRC | |
| SCHEMBL30469290 | 0.83 | AKR1C3 (0.60) | NPC1RAB9AAKR1C3AKR1C2PTPRC | |
| SCHEMBL20557366 | 0.83 | AKR1C3 (0.60) | NPC1RAB9AAKR1C3AKR1C2PTPRC | |
| SCHEMBL8051514 | 0.81 | ALDH1A1 (0.67) | NPC1RAB9APTPRCLMNATSHR | |
| SCHEMBL4056629 | 0.80 | RAB9A (0.63) | NPC1RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL11691049 | 0.80 | ALDH1A1 (0.51) | NPC1RAB9APTPRCLMNAMAPT | |
| SCHEMBL8711545 | 0.79 | ALDH1A1 (0.60) | NPC1RAB9APTPRCLMNATSHR | |
| SCHEMBL30532372 | 0.79 | AKR1C3 (0.57) | NPC1RAB9AAKR1C3AKR1C2PTPRC | |
| SCHEMBL5004567 | 0.79 | ALDH1A1 (0.55) | NPC1RAB9APTPRCLMNATSHR | |
| SCHEMBL26127064 | 0.79 | PTPRC (0.54) | NPC1RAB9APTPRCLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109705097-A | Indazole -3- carboxylic acid amides and its purposes as WNT/ β-CATENIN signal transduction pathway inhibitor | 萨穆梅德有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-105283443-B | Hete rocyclic derivatives and application thereof | 株式会社C&C新药研究所 | 2018-08-17 | — | — | CN | disclosed |
| CN-107980042-A | As ROR gamma agonists and for treating aryl dihydro -2H- benzos [b] [1,4] oxazines sulfonamide and the related compound of disease | 莱斯拉公司 | 2018-05-01 | — | — | CN | disclosed |
| CN-107231802-A | Heterocyclic derivatives and use thereof | 株式会社C&C新药研究所 | 2017-10-03 | — | — | CN | disclosed |
| CN-104219954-B | Benzamide derivatives | 翻译基因组学研究院 | 2017-03-22 | — | — | CN | disclosed |
| CN-103958500-B | Kinases inhibitor | ORION CORP. (FI) | 2016-04-27 | — | — | CN | disclosed |
| CN-105283443-A | Heterocyclic derivatives and use thereof | C & C RES LAB | 2016-01-27 | — | — | CN | disclosed |
| CN-103402996-B | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2015-02-11 | — | — | CN | disclosed |
| CN-104219954-A | Benzamide derivatives | TRANSLATIONAL GENOMICS RES INST | 2014-12-17 | — | — | CN | disclosed |
| CN-103965134-A | N, S-containing heterocyclic compound with nematicidal activity, preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2014-08-06 | — | — | CN | disclosed |
| CN-103929963-A | Indazole-3-carboxamides and their use as WNT/beta-CATENIN signaling pathway inhibitors | SAMUMED LLC | 2014-07-16 | — | — | CN | disclosed |
| CN-1303043-C | Process for producing biaryl compound | SUMITOMO CHEMICAL CO (JP) | 2007-03-07 | — | — | CN | disclosed |
| CN-1642879-A | Process for preparing diaryl compounds | SUMITOMO CHEMICAL CO (JP) | 2005-07-20 | — | — | CN | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | NPC1 875/4885RAB9A 1092/4885AKR1C3 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.